Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction

Typeset version

 

TY  - JOUR
  - Behboudi S., Moore A.C., Gilbert S., Nicoll C.L. and Hill A.V.S. 
  - 2004
  - January
  - Vaccine
  - Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction
  - Published
  - ()
  - 22
  - 4326
  - 4331
  - http://www.sciencedirect.com/science?_ob=ArticleURL;_udi=B6TD4-4CJV6WW-J;_user=77869;_coverDate=10%2F22%2F2004;_rdoc=1;_fmt=high;_orig=search;_sort=d;_docanchor=;view=c;_acct=C000006258;_version=1;_urlVersion=0;_userid=77869;md5=f9a98e913322b835b366c1c2d8
  - 10.1016/j.vaccine.2004.04.029
DA  - 2004/01
ER  - 
@article{V12012113,
   = {Behboudi S., Moore A.C., Gilbert S., Nicoll C.L. and Hill A.V.S. },
   = {2004},
   = {January},
   = {Vaccine},
   = {Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction},
   = {Published},
   = {()},
   = {22},
  pages = {4326--4331},
   = {http://www.sciencedirect.com/science?_ob=ArticleURL;_udi=B6TD4-4CJV6WW-J;_user=77869;_coverDate=10%2F22%2F2004;_rdoc=1;_fmt=high;_orig=search;_sort=d;_docanchor=;view=c;_acct=C000006258;_version=1;_urlVersion=0;_userid=77869;md5=f9a98e913322b835b366c1c2d8},
   = {10.1016/j.vaccine.2004.04.029},
  source = {IRIS}
}
AUTHORSBehboudi S., Moore A.C., Gilbert S., Nicoll C.L. and Hill A.V.S.
YEAR2004
MONTHJanuary
JOURNAL_CODEVaccine
TITLEDendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction
STATUSPublished
TIMES_CITED()
SEARCH_KEYWORD
VOLUME22
ISSUE
START_PAGE4326
END_PAGE4331
ABSTRACT
PUBLISHER_LOCATION
ISBN_ISSN
EDITION
URLhttp://www.sciencedirect.com/science?_ob=ArticleURL;_udi=B6TD4-4CJV6WW-J;_user=77869;_coverDate=10%2F22%2F2004;_rdoc=1;_fmt=high;_orig=search;_sort=d;_docanchor=;view=c;_acct=C000006258;_version=1;_urlVersion=0;_userid=77869;md5=f9a98e913322b835b366c1c2d8
DOI_LINK10.1016/j.vaccine.2004.04.029
FUNDING_BODY
GRANT_DETAILS